A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Phase 2a study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir
and TD-6450 in combination with Ribavirin for a 12-week treatment duration in treatment-naïve
participants with genotype 4 hepatitis C virus (HCV) infection.